Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Net Income | -238.46M | -184.65M | -144.34M | -82.28M | -67.04M |
| Total Depreciation and Amortization | 271.88M | 285.90M | 297.41M | 237.64M | 311.67M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 653.35M | 599.06M | 570.49M | 629.21M | 501.28M |
| Change in Net Operating Assets | -104.63M | -93.29M | 14.08M | -35.09M | 41.55M |
| Cash from Operations | 582.15M | 607.03M | 737.65M | 749.49M | 787.45M |
| Capital Expenditure | -211.54M | -215.74M | -219.15M | -205.82M | -208.96M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -467.25M | -405.01M | -- | 0.00 | 0.00 |
| Divestitures | 176.56M | 60.10M | 17.44M | 17.44M | 17.44M |
| Other Investing Activities | -4.02M | -11.04M | -7.61M | -4.24M | 11.27M |
| Cash from Investing | -506.25M | -571.69M | -209.32M | -192.62M | -180.25M |
| Total Debt Issued | 1.53B | 1.72B | 1.23B | 1.18B | 1.30B |
| Total Debt Repaid | -1.21B | -1.56B | -1.35B | -1.32B | -1.39B |
| Issuance of Common Stock | 2.33M | 1.94M | 714.00K | 771.00K | 1.55M |
| Repurchase of Common Stock | -324.07M | -215.83M | -360.67M | -360.70M | -461.39M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.57M | -37.84M | -54.98M | -58.19M | -65.43M |
| Cash from Financing | -21.42M | -83.68M | -536.73M | -560.74M | -615.66M |
| Foreign Exchange rate Adjustments | 1.36M | 14.81M | 18.83M | 1.45M | 12.19M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 55.84M | -33.53M | 10.43M | -2.42M | 3.74M |